Ubiquigent obtains an exclusive license for the UbiSite technology to strengthen its specialized drug discovery services

Ubiquigent Limited (Ubiquigent), a drug discovery and development company using novel deubiquitylase (DUB) modulators as new therapeutics for areas of high unmet medical need, has signed an exclusive license for UbiSite with the University of Southern Denmark® Technology.

UbiSite will form a new component in Ubiquigent’s DUB and Ubiquitin Proteasome System (UPS) focused drug discovery platform and will provide a fully supported Ubiquitomics service to facilitate target identification, target validation and compound mechanism of action.

The UbiSite technology uses an antibody specific for the C-terminus of ubiquitin to capture and further identify protein ubiquitination sites in cell and tissue samples, allowing for more detailed analysis to gain deeper insight into the ubiquitome. The validated out-of-the-box service can distinguish between ubiquitin and ubiquitin-like modifications such as SUMO, Nedd8 and ISG15 on lysine residues as well as on recently identified serine and threonine residues.

We are pleased to have signed an exclusive license agreement for the UbiSite technology. UbiSite provides an additional layer to Ubiquigent’s drug discovery and development capabilities, allowing us to fully support our customers with a validated Ubiquitomics service, enabling deeper insights into the ubiquitome, as well as the development of our own portfolio of novel DUB modulators and related products to strengthen drug research programs.

dr Sheelagh Frame, Chief Scientific Officer, Ubiquigent

DUBs regulate ubiquitylation, the key to cellular protein homeostasis, activity, and degradation, and therefore hold enormous potential as exciting new drug discovery targets. We are pleased to license our UbiSite technology to Ubiquigent, a company strongly positioned to facilitate DUB-focused drug discovery programs and advance advances in this largely untapped area.

Professor Blagoy Blagoev, Academic Inventor of UbiSite Technology, University of Southern Denmark

By using UbiSite technology in an important collaborative research project, my lab was able to obtain Ubiquitomics data that we previously could not achieve using alternative methods. UbiSite will be a great addition to Ubiquigent’s end-to-end drug discovery platform, further expanding the reach of the company’s services and capabilities.

Professor Sir Philip Cohen, Chair of the Scientific Advisory Board, Ubiquigent


Leave a Reply

Your email address will not be published. Required fields are marked *